接受初次或间歇性肿瘤细胞减灭术的卵巢癌患者30天非计划再入院:系统文献综述
本文系统综述2008年1月1日至2018年1月1日 MEDLINE 收录的英文文献,分析晚期卵巢上皮性癌初次治疗患者30天再入院率、危险因素与预测因素。再入院率为2.5%–19.3%,新辅助化疗联合间歇性肿瘤细胞减灭术(NACT-ICS)较初次肿瘤细胞减灭术(PDS)再入院率更低。
要点
- 卵巢癌初次治疗患者30天再入院率为2.5%–19.3%。
- NACT-ICS 较 PDS 再入院率更低。
- 再入院预测因素包括合并症、再次手术和出院后重大并发症。
核心结论
- 政策与项目应设计用于测量该患者群体的短期和长期结局,以避免在将患者分配至NACT-ICS时产生偏倚,从而维持较低的30天再入院率。
研究设计与样本
- 对2008年1月1日至2018年1月1日期间发表的英文文献进行为期10年的MEDLINE(PubMed)检索,以筛选适合综述的研究。
主要发现
- 接受初次治疗的卵巢癌患者30天再入院率为2.5%–19.3%。
- 与初次肿瘤细胞减灭术(PDS)相比,新辅助化疗联合间歇性肿瘤细胞减灭术(NACT-ICS)与更低的再入院率相关。
- 导致再入院的最常见不良事件包括肠梗阻/小肠梗阻的住院处理、伤口相关并发症和血栓栓塞事件。
- 再入院预测因素包括存在其他内科合并症、再次手术以及初次出院后发生的重大并发症。
- 部分研究报告接受NACT-ICS治疗的患者再入院率和生存率更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Thirty-day readmission rate has been proposed as metric of quality and remains an ongoing clinical concern in the primary treatment of patients with advanced-stage ovarian epithelial ovarian cancer. We conducted a review of the literature to identify rates, risk factors, and predictors for 30-day readmission in this population. METHODS: A 10-year period MEDLINE (PubMed) search of English literature studies published between January 01, 2008-January 01, 2018 was performed to identify appropriate studies for review. RESULTS: Thirty -day readmission rates for ovarian cancer patients undergoing primary treatment ranged from 2.5-19.3%. Neoadjuvant chemotherapy and interval cytoreductive surgery (NACT-ICS) surgery was associated with lower readmission rates, when compared to primary debulking surgery (PDS). The most frequently reported adverse events resulting in readmission include inpatient management of ileus/small bowel obstruction, wound-related complications, and thromboembolic events. Readmission predictors included the presence of other medical comorbidities, re-operation, and major complications occurring after initial hospital discharge. Some studies reported lower rates of readmission and survival in patients treated by NACT-ICS. CONCLUSIONS: Policies and programs should be designed to measure short- and long-term outcomes in this patient population to avoid bias in assigning patients to NACT-ICS to maintain low 30-day readmission rates.
引用
- Clark RM, Rice LW, Del Carmen MG, et al. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review. Gynecol Oncol. 2018. PMID: 29929923. doi:10.1016/j.ygyno.2018.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。